-
2024.3.9
Small cell lung carcinoma initially presenting as giant left ventricular mass.
著者 Yamaguchi O, Kaira K, Imai H, Kagamu H.
Jpn J Clin Oncol. 2024 Mar 9;54(3):359-360. doi: 10.1093/jjco/hyad173.
PMID: 38088026 No abstract available.
-
2024.3.1
Drastic response of sunitinib after failure of Lenvatinib in patients with previously treated thymic carcinoma.
著者 Kaira K, Imai H, Kagamu H.
Lung Cancer. 2024 Mar;189:107501. doi: 10.1016/j.lungcan.2024.107501. Epub 2024 Feb 9.
PMID: 38342048 No abstract available.
-
2024.2.20
Immunotherapy With Radiotherapy for Brain Metastases in Patients With NSCLC: NEJ060.
著者 Tozuka T, Minegishi Y, Yamaguchi O, Watanabe K, Toi Y, Saito R, Nagai Y, Tamura Y, Shoji T, Odagiri H, Ebi N, Sakai K, Kanaji N, Izumi M, Soda S, Watanabe S, Morita S, Kobayashi K, Seike M.
JTO Clin Res Rep. 2024 Feb 20;5(4):100655. doi: 10.1016/j.jtocrr.2024.100655.
PMID: 38706978; PMCID: PMC11069015.
-
2024.2.1
Osimertinib with Chemotherapy in EGFR- Mutated NSCLC. Reply.
著者 Planchard D, Jänne PA, Kobayashi K.
N Engl J Med. 2024 Feb 1;390(5):478-479. doi: 10.1056/NEJMc2314600.
PMID: 38294984.
-
2024.2.1
Clinical significance of antinuclear antibody as prognostic marker for first-line pembrolizumab in advanced non-small cell lung cancer.
著者 Mouri A, Kaira K, Yamaguchi O, Hashimoto K, Miura Y, Shiono A, Kawasaki T, Kobayashi K, Imai H, Kagamu H.
Int J Clin Oncol. 2024 Feb;29(2):124-133. doi: 10.1007/s10147-023-02445-4. Epub 2023 Dec 31.
PMID: 38160406
-
2024.1.19
Clinical impact of inflammatory and nutrition index based on metabolic tumor activity in non‑small cell lung cancer treated with immunotherapy.
著者 Ito K, Hashimoto K, Kaira K, Yamaguchi O, Mouri A, Shiono A, Miura Y, Kobayashi K, Imai H, Kuji I, Kagamu H.
Oncol Lett. 2024 Jan 19;27(3):110. doi: 10.3892/ol.2024.14243. eCollection 2024 Mar.
PMID: 38304175 Free PMC article.
-
2024.1.10
Risk Factors for Bleeding Events in Japanese Patients with Advanced Lung Cancer: Data from the Rising-VTE/NEJ037 Study.
著者 Kawakado K, Tsubata Y, Hotta T, Yamasaki M, Ishikawa N, Fujitaka K, Kubota T, Kobayashi K, Isobe T.
Cancers (Basel). 2024 Jan 10;16(2):301. doi: 10.3390/cancers16020301.
PMID: 38254791; PMCID: PMC10814048.
-
2023.12.2
A phase II study of atezolizumab with bevacizumab, carboplatin, and paclitaxel for patients with EGFR-mutated NSCLC after TKI treatment failure (NEJ043 study).
著者 Watanabe S, Furuya N, Nakamura A, Shiihara J, Nakachi I, Tanaka H, Nakao M, Minato K, Seike M, Sasaki S, Kisohara A, Takeuchi S, Honda R, Takamura K, Kagamu H, Yoshimura K, Kobayashi K, Kikuchi T.
ur J Cancer. 2024 Jan;197:113469. doi: 10.1016/j.ejca.2023.113469. Epub 2023 Dec 2.
PMID: 38061214.
-
2023.12.2
CNS Efficacy of Osimertinib With or Without Chemotherapy in Epidermal Growth Factor Receptor- Mutated Advanced Non-Small-Cell Lung Cancer.
著者 Jänne PA, Planchard D, Kobayashi K, Cheng Y, Lee CK, Valdiviezo N, Laktionov K, Yang TY, Yu Y, Kato T, Jiang L, Chewaskulyong B, Lucien Geater S, Maurel JM, Rojas C, Takahashi T, Havel L, Shepherd FA, Tanaka K, Ghiorghiu D, Amin NP, Armenteros-Monterroso E, Huang X, Chaudhry AA, Yang JC.
J Clin Oncol. 2024 Mar 1;42(7):808-820. doi: 10.1200/JCO.23.02219. Epub 2023 Dec 2.
PMID: 38042525; PMCID: PMC10906563.
-
2023.11.27
Predictive significance of circulating tumor DNA against patients with T790M-positive EGFR-mutant NSCLC receiving osimertinib.
著者 Yamaguchi O, Kasahara N, Soda H, Imai H, Naruse I, Yamaguchi H, Itai M, Taguchi K, Uchida M, Sunaga N, Maeno T, Minato K, Tomono H, Ogawara D, Mukae H, Miura Y, Shiono A, Mouri A, Kagamu H, Kaira K.
Sci Rep. 2023 Nov 27;13(1):20848. doi: 10.1038/s41598-023-48210-5.
PMID: 38012343 Free PMC article.
-
2023.11.8
Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC.
著者 Planchard D, Jänne PA, Cheng Y, Yang JC, Yanagitani N, Kim SW, Sugawara S, Yu Y, Fan Y, Geater SL, Laktionov K, Lee CK, Valdiviezo N, Ahmed S, Maurel JM, Andrasina I, Goldman J, Ghiorghiu D, Rukazenkov Y, Todd A, Kobayashi K; FLAURA2 Investigators.
N Engl J Med. 2023 Nov 23;389(21):1935-1948. doi: 10.1056/NEJMoa2306434. Epub 2023 Nov 8.
PMID: 37937763.
-
2023.9.19
Clinical Utility of Inflammatory and Nutritious Index as Therapeutic Prediction of Nivolumab plus Ipilimumab in Advanced Non-Small Cell Lung Cancer.
著者 Yamaguchi O, Kaira K, Imai H, Mouri A, Shiono A, Miura Y, Hashimoto K, Kobayashi K, Kagamu H.
Oncology. 2024;102(3):271-282. doi: 10.1159/000534169. Epub 2023 Sep 19.
PMID: 37725914